Ian Catlett
About Ian Catlett
Ian Catlett is the Scientific Senior Director at Bristol Myers Squibb in Princeton, NJ, with extensive expertise in cytokine signaling, cellular immunology, and pharmaceutical development.
Title
Ian Catlett is currently the Scientific Senior Director at Bristol Myers Squibb in Princeton, New Jersey, United States. His role involves overseeing various scientific initiatives and guiding the direction of research and development efforts within the organization.
Career at Bristol Myers Squibb
Ian Catlett has held several key positions at Bristol Myers Squibb. He started as a Principal Scientist in 2016 for 8 months, followed by a role as Director of Clinical Biomarkers, Innovative Clinical Development, from 2016 to 2021. He then transitioned to his current role as Scientific Senior Director. His contributions have been significant in the areas of immunology and biomarker research.
Previous Experience at Vertex Pharmaceuticals
Before joining Bristol Myers Squibb, Ian Catlett worked at Vertex Pharmaceuticals. His roles included Senior Research Scientist (2012-2014), Research Scientist II (2008-2012), and Research Scientist I (2006-2008). His work at Vertex Pharmaceuticals focused on research and development in immunology and other related fields.
Education and Expertise
Ian Catlett holds a Ph.D. in Microbiology and Immunology from the University of Iowa and a B.S. in Crop and Soil Environmental Sciences from Virginia Tech. He further specialized in Immunology at UC San Diego. His academic background provides a strong foundation for his expertise in cytokine signaling, cellular immunology, and flow cytometry.
Translational Medicine Initiatives
Ian Catlett leads the Deucravacitinib Translational Medicine efforts, particularly in Dermatology and Rheumatology at Bristol Myers Squibb. His work bridges the gap between laboratory research and clinical applications, helping to advance the understanding and treatment of immune-related diseases.